Reflections on FDA Warning to 23andMe

“Reflections on FDA Warning to 23andMe.” by Jim Evans, The Cancer letter.

There‚Äôs been much recent gnashing of teeth (at least within the narrow and rather insular world of do-it-yourself genomics) about the gall of the FDA in choosing to issue a warning letter to 23andMe, effectively shutting down marketing of their direct-to-consumer personal genomic . . . → Read More: Reflections on FDA Warning to 23andMe

Breast Cancer Fund's Work on Environmental Links to Breast Cancer

A column on Breast Cancer Fund’s work on breast cancer and the environment. By Jeanne Rizzo, Huffington Post.

Jeanne Rizzo, president and CEO of the Breast Cancer Fund, has helped the organization to build an impressive track record of advocating for public policy and business practices to ensure safer products and reduce exposures to toxic . . . → Read More: Breast Cancer Fund’s Work on Environmental Links to Breast Cancer

Pfizer Agrees to Pay $55 Million for Illegally Promoting Off-Label Use of Drug

“Pfizer to Pay $55M for Illegally Promoting Off-Label Use of Drug.” Press Release, United States Department of Justice

Pfizer Inc. will pay $55 million plus interest to resolve allegations that Wyeth LLC illegally introduced and caused the introduction into interstate commerce of a misbranded drug, Protonix, between February 2000 and June 2001, the Justice Department . . . → Read More: Pfizer to Pay $55M for Illegally Promoting Off-Label Use of Drug

New 3-D mammograms have benefits, risks

“New 3-D mammograms have benefits, risks.” By Liz Szabo, USA Today

USA TODAY’s Liz Szabo asked screening experts to talk about the risks, limitations and potential benefits of a new screening method, the new 3-D mammogram. The technology, called tomosynthesis, provides three-dimensional images of the breast by using a technology similar to CT scans, or . . . → Read More: New 3-D mammograms have benefits, risks